logo-loader
RNS
Feedback PLC

Feedback PLC - Grant of Options and PDMR dealing

RNS Number : 5314B
Feedback PLC
22 April 2026
 

Feedback plc

 

Grant of Options and PDMR dealing

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces that it has granted a total of 438,148 options to subscribe for new ordinary shares of 1 penny each in the Company ("Ordinary Shares") under the Company's EMI Share Option Scheme (the "Options") to Emma Oswick, Chief Financial Officer as detailed below.

 

The Options are being issued to appropriately incentivise management, as well as to ensure their interests are aligned with that of the Company and its Shareholders. The Options are exercisable at 20 pence per share.  This price reflect the price at which the Company last completed an equity fundraise in November 2024 and represents a premium of 105% per cent to the closing share price on the last trading day before this announcement.

 

The Options will vest in four equal tranches as follows:

 

·      25% vest in three equal sub-tranches annually (8.33% on each of the first, second and third anniversary of grant of 22nd April 2026)

·      25% vest on reported revenue of £8m

·      25% vest on reported revenue of £12m; and

·      25% vest on reported revenue of £20m

 

"Reported Revenue" is either:

 

·      a year's revenue reported in the full year audited financial statements; or

·      12 months' revenue being H2 of the last full year audited financial statements plus H1 of the last published interim financial statements.

 

The Options are exercisable for a period of 5 years from the vesting date.

 

Following the grant of Options, Emma Oswick will hold a total interest in the Company of 438,148 options.  The Options represent in aggregate 1.0% of the Company's existing issued share capital.

 

Following the grant of the Options and taking into account existing options, the Company has a total of 4,481,061 options to subscribe for ordinary shares in the Company in issue, representing 10.2% of the Company's issued share capital at the date of this announcement.

 

 

Further information on Feedback and its products can be found on the Company's website: https://feedbackmedical.com

 

--Ends--

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Emma Oswick, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 


Panmure Liberum Limited (NOMAD and Broker)

Emma Earl/Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 


Walbrook PR Ltd;

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Nick Rome/Marcus Ulker

07748 325 236 or 07867 984 082

 

 

About Feedback plc

 

Feedback plc is the strategic partner to unlock productivity in health and care through digital connectivity and asynchronous collaboration. With proven expertise in system integration, we enable teams to work flexibly, share information securely, and deliver care more efficiently.

 

Bleepa® is an award-winning collaboration platform that improves the quality and productivity of patient pathways enabling health and care organisations to hit targets with their existing clinical workforce. We achieve this by connecting digital infrastructure across systems, enabling asynchronous working, reducing geographic barriers and removing unnecessary appointments.

 

Bleepa supports the shift from analogue to digital and from hospital to community-based care, by uniting essential data and teams to enhance clinical decision making and enable better coordinated care.

 

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

https://fbk.com

 

 

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities under UK MAR

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Emma Oswick

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR - Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Feedback plc

b)

 

LEI

 

 

213800UGOF2GT2U2RV90

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of 1 penny each

 

 

 

GB00BJN59X09

b)

 

Nature of the transaction

 

Grant of options to subscribe for Ordinary Shares

 

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

Nil

438,148

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

 

Date of the transaction

 

22nd April 2026

 

f)

 

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCXLLFLQZLBBBV
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read